Clinical information
Diagnostic Utility:
This is the qualitative detection of IgG antibodies against the parasite Trypanosoma cruzi. Its determination is useful in:
- Diagnosing infection by T. cruzi
- Screening to prevent the transmission of T. cruzi to blood recipients, blood derivatives, cells, tissues, and organs.
Method:
Chemiluminescent microparticle immunoassay (CMIA).
Reference Values
Possible results are: Reactive and Non-reactive.
Diagnostic Algorithm:
In case of a reactive result for Trypanosoma cruzi anti-IgG, the complementary test can be requested:
| Code | Test Name | Can it be requested separately? | Is it always performed? |
|---|---|---|---|
| 0198 | Trypanosoma cruzi, DNA | Yes | No (*) |
(*) Only performed upon request and whole blood is needed.
Response Time:
Maximum 2 working days.
Specimen information
Sample: Serum and/or plasma.
Tube: 1-5 mL aliquots, plasma tubes with EDTA, potassium oxalate, sodium citrate, ACD, CP2D, CPD, or CPDA-1 as anticoagulant and/or serum tubes with and without gel separator.
Minimum essential volume: 1 ml
Stability:
- At 15-30 °C : ≤ 3 days
- In refrigeration at 2-8 °C: ≤ 14 days
- Sample frozen at or below -20°C: 10 years
Transport instructions: Preferably at room temperature and/or refrigerated if they are whole blood tubes and frozen if they are serum and/or plasma aliquots.
Reason for rejection: Plasma tubes with heparin as anticoagulant.
Administrative information
BST Code: 0197
Test Description: Trypanosoma cruzi, IgG Antibodies. Screening
Synonyms: Section: Transfusion Safety Laboratory
BST Rate: Check the updated rates here.
Profiles:
Not applicable.
References
- Inserts kits test ABBOTT ARCHITECT Chagas
Quality
BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.